

## **AmerisourceBergen Reports Record March Quarter as Early Synergy Capture and Interest Savings Drive Results**

April 25, 2002

### ***March Quarter EPS Up 53 Percent To \$0.87 Before Special Charges***

VALLEY FORGE, Pa., Apr 25, 2002 (BUSINESS WIRE) --AmerisourceBergen Corporation (NYSE:ABC) today reported record results for its fiscal second quarter and six months ended March 31, 2002.

AmeriSource Health Corporation and Bergen Brunswig Corporation merged on August 29, 2001 to form AmerisourceBergen Corporation. Under purchase accounting rules, AmerisourceBergen's fiscal 2002 second quarter and six-month results are compared with the fiscal 2001 second quarter and six-month results of AmeriSource only.

Pro forma data included in this discussion reflects comparisons to the combined companies' operating results in the previous year's second quarter and first six months, adjusted to eliminate amortization of goodwill. Both former companies had the same fiscal year ending September 30.

Diluted earnings per share before special charges for the quarter were \$0.87, a 53 percent increase over the previous year's second quarter. Income before the special charges for the second quarter increased to \$94.7 million from \$31.5 million in the same period last year.

The special charges, consisting of merger integration costs, were \$2.9 million, net of tax, in the quarter. Net income and diluted earnings per share for the quarter were \$91.9 million and \$0.84, respectively.

AmerisourceBergen's operating revenue, which excludes bulk deliveries to customer warehouses, was \$9.9 billion in the second quarter compared to \$3.5 billion for the same period last year. Second quarter operating revenue increased 17 percent over fiscal 2001 second quarter pro forma operating revenue of \$8.5 billion.

For the first six months of fiscal 2002, diluted earnings per share before special charges were \$1.54, a 44 percent increase over the prior year. Operating revenue for the six-month period was \$19.6 billion compared to \$6.8 billion in the prior year, and represents an 18 percent increase over pro forma operating revenue of \$16.6 billion in the first half of fiscal 2001.

Net income and diluted earnings per share for the six-month period were \$159.8 million and \$1.48, respectively.

For the second quarter of fiscal 2002, interest expense, including pretax distributions on preferred securities of subsidiary trust, was \$38.8 million, reflecting effective asset management and favorable interest rates.

The following discussion of results, including segment data, does not include the impact of the special charges in the second quarter and first six months of fiscal 2002.

R. David Yost, AmerisourceBergen President and Chief Executive Officer, said, "This was an outstanding performance by AmerisourceBergen, reflecting our ability to rapidly leverage the cost saving and scale synergies of our new company. We have succeeded in capturing merger synergies earlier than we expected. Improved capital management and a historically low interest rate environment also positively impacted the Company's performance. These factors drove operating margin expansion, record earnings per share, significant cash generation, and a very strong return on committed capital (ROCC).

"I am very pleased with the progress we are making in bringing these two companies together. Our synergy opportunities and our discipline in both capital usage and expense control will continue to drive our results."

### Segment Discussion

AmerisourceBergen operates in two segments: Pharmaceutical Distribution (which includes AmerisourceBergen Drug Company and AmerisourceBergen Specialty Group) and PharMerica, AmerisourceBergen's institutional pharmacy and workers' compensation fulfillment businesses.

Intersegment sales of \$192.1 million in the second quarter of fiscal 2002 from AmerisourceBergen Drug Company to PharMerica, which are included in the pharmaceutical distribution segment operating revenue, are eliminated for consolidated reporting purposes.

### Pharmaceutical Distribution Segment

Operating revenue in the second quarter of fiscal 2002 increased to \$9.8 billion compared with \$3.5 billion in the previous year's second quarter. Operating revenue increased 17 percent over fiscal 2001 second quarter pro forma revenues of \$8.3 billion.

Pharmaceutical distribution customer mix in the second quarter of fiscal 2002 was 52 percent institutional and 48 percent retail. AmerisourceBergen is the market leader in pharmaceutical distribution to hospital systems and acute care facilities, alternate care and mail order facilities, independent community pharmacies, and regional chain store pharmacies.

Operating income was \$176.0 million in the second quarter of fiscal year 2002, up from \$64.4 million for the same quarter last year, and improved 22 percent compared to pro forma operating income of \$144.7 million in the same period last year.

For the fiscal 2002 second quarter, operating income, as a percentage of operating revenue, was 1.80 percent, a six basis point improvement from 1.74 percent in the prior year's second quarter on a pro forma basis, as lower gross margins were more than offset by lower total operating expenses

as a percentage of operating revenue.

AmerisourceBergen Specialty Group, with annualized revenue well over \$2 billion, had another very strong quarter, building significant positions in oncology, blood plasma and vaccine distribution as well as growing its manufacturing services businesses.

"We are pleased with both the pace and progress of our integration work. Our detailed planning and disciplined execution has allowed us to put the right people, organization and resources in place to quickly capture integration cost savings ahead of our internal schedule," said Kurt J. Hilzinger, AmerisourceBergen Executive Vice President and Chief Operating Officer. "During the quarter, we completed on schedule the information technology integration work that will allow us to consolidate five additional distribution centers by the end of September. The first of these, in Phoenix, Arizona, is on track to be completed this week.

"At the end of the quarter, we launched our new generic pharmaceutical program, ProGenerics(TM), which provides significant value for both our customers and participating manufacturers, and will further contribute to our profitability in the second half of the year."

#### PharMerica

PharMerica's operating revenue for the second quarter of fiscal 2002 was \$359.8 million, representing a 6 percent increase over pro forma operating revenue of \$339.9 million in the same period last year.

Operating income for the second quarter was \$19.5 million, a 21 percent increase over the prior year's pro forma second quarter operating income of \$16.1 million.

Operating income as a percentage of operating revenue increased 69 basis points in the quarter to 5.43 percent from 4.74 percent on a pro forma basis in the prior year.

"Cost savings from expense control, driven by the favorable impact of a single information technology platform and continued accounts receivables discipline, improved PharMerica's performance in the quarter," said Hilzinger.

#### Looking Ahead

"We expect continued strong performance for AmerisourceBergen with revenue growth for fiscal year 2002 in the range of 15 percent to 17 percent and ROCC in excess of 20 percent," said Yost. "We are increasing our diluted earnings per share estimate for fiscal year 2002, excluding the impact of merger-related special charges, from \$3.00 to \$3.15. The increase in earnings expectations for the year reflects the strong performance of our businesses in the second quarter, continued low interest rates, and our ongoing focus on cost improvement. We remain confident in our ability to achieve annual cost saving synergies of \$150 million by the end of fiscal year 2004."

#### Conference Call

The Company will host a conference call to discuss the results at 11:00 am Eastern Daylight Time on April 25, 2002. Participating in the conference call will be: R. David Yost, President & Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President & Chief Operating Officer; and Michael D. DiCandilo, Senior Vice President & Chief Financial Officer.

To access the live conference call via telephone:

Dial in: 888/428-4473 from inside the U.S. no access code required  
or 651/291-0561 from outside the U.S. no access code  
required.

To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at <http://www.amerisourcebergen.net>.

A replay of the telephone call and webcast will be available from 2:30 pm April 25, 2002 until 11:59 pm May 2, 2002.

To access the replay via telephone:

Dial in: 800/475-6701 from within the U.S., access code: 634155  
320/365-3844 from outside the U.S., access code: 634155

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at <http://www.amerisourcebergen.net>.

#### About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternate care and mail order facilities, independent community pharmacies, and regional chain pharmacies.

The Company is also a leader in the institutional pharmacy marketplace. With more than \$39 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

## Forward-Looking Statements

This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.

Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between Amerisource Health Corporation and Bergen Brunswig Corporation.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2001, Form 10-Q for the first quarter of fiscal 2002, and AmeriSource's and Bergen's joint proxy statement-prospectus dated August 1, 2001.

AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

### AMERISOURCEBERGEN CORPORATION

#### FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

	Three Months Ended March 31, 2002	Three Months Ended March 31, 2001	% of Operating Revenue	% of Operating Revenue	% Change
Revenue:					
Operating revenue	\$9,918,609	\$3,480,685	100.00%	100.00%	185%
Bulk deliveries to customer warehouses	1,025,658	313		-	
Total revenue	10,944,267	3,480,998		214%	
Cost of goods sold	10,429,774	3,329,829		213%	
Gross profit	514,493	151,169	5.19%	4.34%	240%
Operating expenses:					
Distribution, selling and administrative	304,576	82,462	3.07%	2.37%	269%
Depreciation and amortization	14,402	4,281	0.15%	0.12%	236%
Merger costs	4,741	-	0.05%	0.00%	-
Operating income	190,774	64,426	1.92%	1.85%	196%
Equity in (income) losses of affiliates and other	(354)	1,801	0.00%	0.05%	-120%
Interest expense	32,734	11,793	0.33%	0.34%	178%
Income before taxes and distributions					

on preferred securities of subsidiary trust	158,394	1.60%	50,832	1.46%	212%
Income taxes	62,891	0.63%	19,316	0.55%	226%

Income before distributions on preferred securities of subsidiary trust	95,503	0.96%	31,516	0.91%	203%
---	--------	-------	--------	-------	------

Distributions on preferred securities of subsidiary trust, net of income tax benefit of	\$2,389	3,629	0.04%	-	0.00%	-
---	---------	-------	-------	---	-------	---

Net income	\$ 91,874	0.93%	\$ 31,516	0.91%	192%
------------	-----------	-------	-----------	-------	------

Earnings per share:					
Basic	\$ 0.88		\$ 0.60		
Diluted	\$ 0.84		\$ 0.57		

Weighted average common shares outstanding:					
Basic	104,404		52,701		
Diluted	111,704		59,349		

Pro forma results excluding merger costs in the three months ended March 31, 2002:

Operating income	\$ 195,515		\$ 64,426		
Net income	\$ 94,734		\$ 31,516		

Earnings per share:					
Basic	\$ 0.91		\$ 0.60		
Diluted	\$ 0.87		\$ 0.57		

AMERISOURCEBERGEN CORPORATION  
FINANCIAL SUMMARY

(In thousands, except per share data)  
(unaudited)

Six		Six	
Months Ended	% of	Months Ended	% of
March 31, 2002	Operating Revenue	March 31, 2001	Operating Revenue
			Change

Revenue:					
Operating revenue	\$19,604,885	100.00%	\$6,787,436	100.00%	189%
Bulk deliveries to customer warehouses	2,408,162		757	--	
Total revenue	22,013,047		6,788,193		224%
Cost of goods sold	21,027,121		6,499,591		224%

Gross profit	985,926	5.03%	288,602	4.25%	242%
Operating expenses:					
Distribution, selling and administrative	602,168	3.07%	162,107	2.39%	271%
Depreciation and amortization	29,449	0.15%	8,175	0.12%	260%
Merger costs	12,238	0.06%	--	0.00%	--
	-----	-----			
Operating income	342,071	1.74%	118,320	1.74%	189%
Equity in losses of affiliates and other	1,377	0.01%	2,575	0.04%	-47%
Interest expense	63,709	0.32%	22,669	0.33%	181%
	-----	-----			
Income before taxes and distributions on preferred securities of subsidiary trust	276,985	1.41%	93,076	1.37%	198%
Income taxes	109,969	0.56%	35,369	0.52%	211%
	-----	-----			
Income before distributions on preferred securities of subsidiary trust	167,016	0.85%	57,707	0.85%	189%
Distributions on preferred securities of subsidiary trust, net of income tax benefit of \$4,777	7,259	0.04%	--	0.00%	--
	-----	-----			
Net income	\$159,757	0.81%	\$57,707	0.85%	177%
	=====	=====			
Earnings per share:					
Basic	\$1.54		\$1.10		
Diluted	\$1.48		\$1.07		
Weighted average common shares outstanding:					
Basic	104,070		52,528		
Diluted	111,443		56,939		
	-----	-----			

Pro forma results excluding merger costs in the six months ended March

31, 2002:

Operating income \$354,309 \$118,320

Net income \$167,137 \$57,707

Earnings per share:

Basic \$1.61 \$1.10

Diluted \$1.54 \$1.07

AMERISOURCEBERGEN CORPORATION  
CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands)

ASSETS (Unaudited)

March 31, September 30, \$  
2002 2001 Change

Current assets:

Cash and cash equivalents \$ 463,815 \$ 297,626 \$ 166,189

Accounts receivable, net 2,061,331 2,142,663 (81,332)

Merchandise inventories 5,295,924 5,056,257 239,667

Prepaid expenses and other 17,831 15,956 1,875

Total current assets 7,838,901 7,512,502 326,399

Long-term assets 2,761,318 2,778,743 (17,425)

Total assets \$10,600,219 \$10,291,245 \$ 308,974

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable \$ 5,076,767 \$ 4,991,884 \$ 84,883

Current portion of long-term debt 30,000 2,468 27,532

Other current liabilities 616,625 538,101 78,524

Total current liabilities 5,723,392 5,532,453 190,939

Long-term debt, less

current portion 1,508,889 1,597,295 (88,406)

Other liabilities 43,260 48,317 (5,057)

Company-obligated mandatorily redeemable

preferred securities of subsidiary trust 274,952 274,616 336

Stockholders' equity 3,049,726 2,838,564 211,162

Total liabilities and stockholders' equity \$10,600,219 \$10,291,245 \$ 308,974

AMERISOURCEBERGEN CORPORATION  
SUMMARY SEGMENT INFORMATION

(dollars in thousands)

Three Months Ended March 31,

Operating Actual Actual Pro forma Actual Pro forma  
Revenue 2002 2001 2001 (1) % Change % Change

Pharmaceutical

Distribution \$9,750,903 \$3,480,685 \$8,335,337 180% 17%

PharMerica 359,761 - 339,924 - 6%

Intersegment

Eliminations (192,055) - (207,285) - -7%

Operating

revenue \$9,918,609 \$3,480,685 \$8,467,976 185% 17%

Three Months Ended March 31,

Operating Income (2)	Actual 2002	Actual 2001	Pro forma 2001 (1)	Actual % Change	Pro forma % Change
-----					
Pharmaceutical					
Distribution	\$175,968	\$64,426	\$144,714	173%	22%
PharMerica	19,547	-	16,114	-	21%
-----					
Operating income	\$195,515	\$64,426	\$160,828	203%	22%
=====					

Percentages of  
operating revenue (2):

-----					
Pharmaceutical					
Distribution					
Gross profit	4.04%	4.34%	4.30%		
Operating					
expenses	2.23%	2.49%	2.56%		
Operating income	1.80%	1.85%	1.74%		
PharMerica					
Gross profit	33.52%	-	35.81%		
Operating					
expenses	28.09%	-	31.07%		
Operating income	5.43%	-	4.74%		
AmerisourceBergen					
Corporation					
Gross profit	5.19%	4.34%	5.67%		
Operating					
expenses	3.22%	2.49%	3.77%		
Operating income	1.97%	1.85%	1.90%		

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes merger costs.

AMERISOURCEBERGEN CORPORATION  
SUMMARY SEGMENT INFORMATION  
(dollars in thousands)  
Six Months Ended March 31,

Operating Revenue	Actual 2002	Actual 2001	Pro forma 2001 (1)	Actual % Change	Pro % form
-----					
Pharmaceutical					
Distribution	\$19,272,979	\$ 6,787,436	\$16,265,303	184%	18%
PharMerica	715,176	-	675,090	-	6%
Intersegment					
Eliminations	(383,270)	-	(388,882)	-	-1%
-----					
Operating revenue	\$19,604,885	\$ 6,787,436	\$16,551,511	189%	18%
=====					
Six Months Ended March 31,					
-----					

Operating Income (2)	Actual 2002	Actual 2001	Pro forma 2001 (1)	Actual % Change	Pro % form
-----					
Pharmaceutical					
Distribution	\$ 315,452	\$ 118,320	\$ 260,804	167%	21%
PharMerica	38,857	-	33,221	-	17%
-----					

-----					
Pharmaceutical					
Distribution	\$ 315,452	\$ 118,320	\$ 260,804	167%	21%
PharMerica	38,857	-	33,221	-	17%
-----					

Operating  
income \$ 354,309 \$ 118,320 \$ 294,025 199% 21%

=====

Percentages  
of operating  
revenue (2):

Pharmaceutical

Distribution

Gross profit 3.87% 4.25% 4.18%

Operating  
expenses 2.23% 2.51% 2.58%

Operating income 1.64% 1.74% 1.60%

PharMerica

Gross profit 33.57% - 35.83%

Operating expenses 28.14% - 30.91%

Operating income 5.43% - 4.92%

AmerisourceBergen

Corporation

Gross profit 5.03% 4.25% 5.57%

Operating expenses 3.22% 2.51% 3.80%

Operating income 1.81% 1.74% 1.78%

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes merger costs.

AMERISOURCEBERGEN CORPORATION

EARNINGS PER SHARE

(In thousands, except per share data)

(unaudited)

Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the period plus the dilutive effect of stock options.

Additionally, the calculations consider the convertible subordinated notes as if converted and, therefore, the effect of interest expense related to those notes is added back to net income in determining income available to common stockholders.

	Three months ended		Six months ended	
	March 31,	March 31,	March 31,	March 31,
	2002	2001	2002	2001

Net income	\$ 91,874	\$ 31,516	\$ 159,757	\$ 57,707
------------	-----------	-----------	------------	-----------

Interest expense

- convertible  
subordinated

notes, net of income taxes	2,481	2,528	4,961	3,086
-------------------------------	-------	-------	-------	-------

Income available

to common

stockholders	\$ 94,355	\$ 34,044	\$ 164,718	\$ 60,793
--------------	-----------	-----------	------------	-----------

=====

Weighted average

common shares

outstanding	104,404	52,701	104,070	52,528
-------------	---------	--------	---------	--------

Effect of

dilutive

securities:

Options to

purchase common

stock	1,636	984	1,709	988
-------	-------	-----	-------	-----

Convertible

subordinated



notes	5,664	5,664	5,664	3,423
-------	-------	-------	-------	-------

Weighted average  
common shares

outstanding - diluted	111,704	59,349	111,443	56,939
--------------------------	---------	--------	---------	--------

Earnings per  
share:

Basic	\$ 0.88	\$ 0.60	\$ 1.54	\$ 1.10
Diluted	\$ 0.84	\$ 0.57	\$ 1.48	\$ 1.07

Appendix - A(1)

Pro Forma Information

The historical consolidated financial summary and summary segment information for the three-months and six-months ended March 31, 2001, included in this press release, reflect only the results of AmeriSource Health Corporation, as predecessor to the Company. In order to enhance comparability, the following schedules as well as the summary segment information include fiscal 2001 financial data on a pro forma basis. Within these schedules, pro forma refers to the combined results of AmeriSource Health Corporation and Bergen Brunswick Corporation and are not intended to be consolidated financial statements of AmeriSourceBergen prepared in accordance with generally accepted accounting principles and do not represent consolidated results as if the merger had occurred at the beginning of the periods presented. In addition, they are not necessarily indicative of the actual results which might have occurred had the operations and management of AmeriSource Health Corporation and Bergen Brunswick Corporation been combined at the beginning of fiscal 2001.

In addition, to enhance comparability of financial information between fiscal years, the pro forma information for fiscal 2001 excludes the amortization of goodwill and special items related to the merger and environmental remediation and reflects the full allocation of Bergen Brunswick Corporation's former Corporate segment to the Pharmaceutical Distribution and PharMerica segments.

Appendix - A(2)

AmeriSourceBergen

Pro forma combined condensed financial information (1)

(dollars in thousands)

Fiscal Year Ended September 30, 2001

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Fiscal Year
--	------------------	-------------------	------------------	-------------------	-------------

Operating revenue	\$8,083,535	\$8,467,976	\$8,995,115	\$9,052,684	\$34,599,310
----------------------	-------------	-------------	-------------	-------------	--------------

Gross profit	\$442,249	\$480,035	\$475,810	\$482,647	\$1,880,741
--------------	-----------	-----------	-----------	-----------	-------------

Distribution,  
selling and  
administrative

(2)	293,608	303,730	295,462	304,703	1,197,503
Depreciation	13,891	14,337	14,296	14,641	57,165
Amortization (3)	1,553	1,140	1,270	1,427	5,390

Operating income	\$133,197	\$160,828	\$164,782	\$161,876	\$620,683
---------------------	-----------	-----------	-----------	-----------	-----------

Gross profit to  
operating

revenue	5.47%	5.67%	5.29%	5.33%	5.44%
---------	-------	-------	-------	-------	-------

Operating  
expenses to  
operating

revenue	3.82%	3.77%	3.46%	3.54%	3.64%
Operating income to operating revenue	1.65%	1.90%	1.83%	1.79%	1.79%

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes special items in the third and fourth quarters related to the merger and environmental remediation.

(3) Excludes amortization of goodwill.

Appendix - A(3)

AmerisourceBergen - Pharmaceutical Distribution

Pro forma combined condensed financial information (1)

(dollars in thousands)

-----  
Fiscal Year Ended September 30, 2001  
-----

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Fiscal Year
--	---------------	----------------	---------------	----------------	-------------

-----

Operating revenue	\$7,929,966	\$8,335,337	\$8,835,163	\$8,885,145	\$33,985,611
-------------------	-------------	-------------	-------------	-------------	--------------

=====

Gross profit	\$322,096	\$358,294	\$358,619	\$365,948	\$1,404,957
--------------	-----------	-----------	-----------	-----------	-------------

Distribution, selling and administrative (2), (3)	195,464	202,915	200,042	211,501	809,922
---	---------	---------	---------	---------	---------

Depreciation	9,426	9,962	9,916	10,278	39,582
--------------	-------	-------	-------	--------	--------

Amortization (4)	1,116	703	835	972	3,626
------------------	-------	-----	-----	-----	-------

-----

Operating income	\$116,090	\$144,714	\$147,826	\$143,197	\$551,827
------------------	-----------	-----------	-----------	-----------	-----------

=====

Gross profit to operating revenue	4.06%	4.30%	4.06%	4.12%	4.13%
-----------------------------------	-------	-------	-------	-------	-------

Operating expenses to operating revenue	2.60%	2.56%	2.39%	2.51%	2.51%
---	-------	-------	-------	-------	-------

Operating income to operating revenue	1.46%	1.74%	1.67%	1.61%	1.62%
---------------------------------------	-------	-------	-------	-------	-------

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes special items in the fourth quarter related to the merger and environmental remediation.

(3) Expenses previously reported in the Corporate segment for Bergen Brunswig Corporation have been fully allocated to the Pharmaceutical Distribution and PharMerica segments for

comparative purposes within this schedule.

(4) Excludes amortization of goodwill.

Appendix - A(4)

AmerisourceBergen - PharMerica

Pro forma combined condensed financial information (1)

(dollars in thousands)

-----  
Fiscal Year Ended September 30, 2001  
-----

First Second Third Fourth Fiscal Year  
Quarter Quarter Quarter Quarter

-----  
Operating revenue \$335,166 \$339,924 \$336,783 \$338,135 \$1,350,008  
=====

Gross profit \$120,153 \$121,741 \$117,191 \$116,699 \$ 475,784

Distribution,  
selling and  
administrative

(2), (3) 98,144 100,815 95,420 93,202 387,581

Depreciation 4,465 4,375 4,380 4,363 17,583

Amortization (4) 437 437 435 455 1,764

-----  
Operating income \$ 17,107 \$ 16,114 \$ 16,956 \$ 18,679 \$ 68,856  
=====

Gross profit to  
operating

revenue 35.85% 35.81% 34.80% 34.51% 35.24%

Operating  
expenses to

operating  
revenue 30.74% 31.07% 29.76% 28.99% 30.14%

Operating income  
to operating

revenue 5.10% 4.74% 5.03% 5.52% 5.10%

(1) Represents the combination of AmeriSource Health Corporation's and  
Bergen Brunswig Corporation's previously reported financial  
information. (See discussion under Pro Forma Information Appendix  
- A(1)).

(2) Excludes special items in the fourth quarter related to the merger  
and environmental remediation.

(3) Expenses previously reported in the Corporate segment for Bergen  
Brunswig Corporation have been fully allocated to the  
Pharmaceutical Distribution and PharMerica segments for  
comparative purposes within this schedule.

(4) Excludes amortization of goodwill.

Appendix - A(5)

AmerisourceBergen - Intersegment Eliminations

Pro forma combined condensed financial information (1)

(dollars in thousands)

-----  
Fiscal Year Ended September 30, 2001  
-----

First Second Third Fourth Fiscal  
Quarter Quarter Quarter Quarter Year

-----  
Operating  
revenue (\$181,597) (\$207,285) (\$176,831) (\$170,596) (\$736,309)  
=====

Gross profit \$0 \$0 \$0 \$0 \$0

Distribution,  
selling and  
administrative

- - - - -

Depreciation - - - - -

Amortization - - - - -  
-----

Operating  
income            \$0    \$0    \$0    \$0    \$0

=====

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

CONTACT:        AmerisourceBergen, Valley Forge  
                  Michael N. Kilpatric, 610/727-7118  
                  mkilpatric@amerisource.com